index - Epidemiology in dermatology and evaluation of therapeutics

DOCUMENTS

94

 

NOTICES

156

 

 

MOTS CLES

Systematic review Management Spondylitis Ankylosing spondylitis Apre-milast Auto-Diagnostic Biosimilar Pharmaceuticals Etanercept Atrial fibrillation Epidemiology Albinism Stability Amyloidosis Sacroiliitis Pharmacoepidemiology Anti-HCV Direct Acting Antivirals DAA Apremilast Anticancer drugs Méta-Analyse Azathioprine Biologics Cardio-oncology Ustekinumab Antimicrobial resistance Biological therapy Ankylosing Immune checkpoint inhibitors Psoriasis Ethics Endocrine toxicity Quality of life Dermatology Network meta-analysis Antibiotic resistance BTK protein Biologic drug Psoriatic arthritis Drug survival Biologic Cancer Cardiotoxicity Vigibase® Biomédicaments Bacterial rhinosinusitis Accelerometer Biological Therapy Alcohol Adolescent Aging Bacterial Spondyloarthritis Glucocorticoids Anxiety Cardiomyopathy Angiotensin receptor blockers Graft-versus-host disease Antimicrobials Addiction COVID-19 Antimicrobial Stewardship Anxiété Immune-related adverse events Drug reaction Arthritis Anti-TNF Axial spondyloarthritis Antimicrobiens Anti-Bacterial Agents Meta-Analysis Intensive care Angiotensin-converting enzyme inhibitors Treatment Placebo Beta-lactam antibiotics Alitretinoin Sipuleucel-T Burden Pharmacovigilance Antibiotics Autoimmune diseases Auto-immune hepatitis Infliximab Adverse side effects Antibiotic misuse Biomarkers ArtThese Acute Myeloid Leukaemia AML Adalimumab Pregnancy Prostate cancer Atopic dermatitis Immunotherapy Autoimmunity Arrhythmia ASDAS Abus d'antibiotiques Access to care Primary adrenal insufficiency Biologic therapy Pharmaco-Épidémiologie

 

 

 

Epidemiology in Dermatology and Evaluation of therapeutics , EA 7379

Adresse

Université Paris-Est Créteil Val de Marne (UPEC)

Campus Centre de Créteil
61 Avenue du Général de Gaulle
94010 Créteil Cedex

Courriel

emilie.sbidian@aphp.fr

Site Internet

 

Rattachement(s)

UFR de Santé

Direction

Émilie SBIDIAN

 

Axe(s) de recherche

 


[legende-image]65[/legende-image] Axe 1 : Comment mieux gérer les patients ayant développé des réactins graves aux médicaments, notamment en leur indiquant comment utiliser correctement les agents


[legende-image]65[/legende-image] Axe 2 : Rechercher les facteurs associés aux effets indesirables et à l'efficacité du médicament

 
 

COLLABORATIONS